

16.10.2025

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

BSE Security Code : 503229

**Sub: Newspaper Advertisement –regarding launch of ‘Saksham Niveshak’ campaign-
Action required for Unclaimed Dividends and KYC Updates**

Dear Sir/ Madam,

Pursuant to Regulation 30, read with sub-para 12 of Para A, Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of the newspaper advertisement published in the following newspapers, informing shareholders about the commencement of a 100-day special initiative i.e. ‘Saksham Niveshak’, being conducted from July 28, 2025 to November 6, 2025. This initiative is in line with the campaign launched by the Investor Education and Protection Fund Authority (IEPFA) under the Ministry of Corporate Affairs (MCA).

- a. Financial Express - English newspaper and
- b. Mumbai Lakshadeep - Marathi newspaper

This is for your information and records.

Thanking you,

Yours faithfully,
For **Simplex Realty Limited**

POOJA PARESH
BAGWE

Digitally signed by
POOJA PARESH BAGWE
Date: 2025.10.16
12:53:30 +05'30'

Pooja Bagwe
Company Secretary and Compliance officer
Encl.: a/a

CIN: L17110MH1912PLC000351

Registered Office: 30, Keshavrao Khadye Marg, Sant Gadge Maharaj Chowk, Mahalaxmi (E), Mumbai – 400011

T: +91 22 23082951 | E:mail: investors@simplex-group.com

| Website: www.simplex-group.com

company-secretary@simplex-group.com

[illegible]

PUBLIC NOTICE BASF INDIA LTD							
Registered Office: The Capital, A Wing, 12/24-1/26 Floor, Plot No. C-70, G-Block, Bandra Kurla Complex, Mumbai, Maharashtra 400051							
TO WHOMSOEVER IT MAY CONCERN							
NOTICE is hereby given that the certificate[s] for the under mentioned securities of the Company has/have been lost/misplaced and the holder[s] of the said security/ applicant[s] has/have applied to the Company to replace certificate[s].							
Names of the Holders	Folio No/s	Certificate Nos.		Distinctive Nos.		No. of Shares	
		Face Value	Start	End	End		
VIVEK TANNAN AND MEENAL GADGIL	BY90001850	10	338730	338734	24037124	24037293	170
VIVEK TANNAN AND MEENAL GADGIL	BY90001850	10	70000290	70000120	698048	698048	33
VIVEK TANNAN AND MEENAL GADGIL	BY90001850	10	70000400	70000304	1352489	1392881	33
VIVEK TANNAN AND MEENAL GADGIL	BY90001850	10	70001452	70001452	5544125	5542544	130
TOTAL NUMBER OF SHARES						366	
The Public are hereby cautioned against purchasing or dealing in any way with the above referred share certificate[s].							
Any person who has any claim in respect of the said share certificate[s] should lodge such claim with the Company or its Company shall be required to issue with the Duplicate Share Certificate[s]. Place : _____ Name of the holder/s of the said security/ and Transfer Agents : MUFG India Finance Private Limited 247Park, C-101, L.S. B. Marg, Vikhroli (W) Mumbai-400083. Tel: 0181176627 within 15 days of publication of the notice after which no claim will be entertained and the Company shall proceed to issue with the Duplicate Share Certificate[s].							
Place : Mumbai			Vivek Tannan / Meenal Gadgil				
Date : 05/10/2025			Legal Claimant:				


केनरा बैंक Canara Bank
 Asset Reconstruction Management Branch, Mumbai
 Canara Bank Building, 49 Floor, Market Street, Worli East, Mumbai - 400025
 Email :- asr@canarabank.com; Mobile no: 9655045434

POSSESSION NOTICE [Section 13(4)]

(For Immovable Property) CERSA ID - 4000510397

Whereas, the undersigned being the Authorized Officer of Central Board of Secondary Education and Securityization and Enforcement of Financial Assets and Enforcement of Security Interest Act, 2002 (Act of 2002) (hereinafter referred to as "the Act") and in pursuance of the provisions contained in Section 13 (12) read with Section 13 (2) of the said Act (Enforcement Rules), 2002, issued a Demand Notice dated 31.07.2023 calling upon the Borrowers/Mortgagor's/Guarantors i.e. **Mrs. Wasit Band Garments Pvt Ltd**, **Bhaskar Bhatia**, **Rishabh Kumar Singh**, **Sandeep Kumar Singh**, **Prashant Kumar Singh**, **Rishiendra Singh (Director)** & **Priya Pradyashini (Mortgagor & Guarantor)** to repay the amount mentioned in the notice, being Rs. 1,13,39,528.38 (Rupees Eleven Crores Thirteen Lakhs Three Thousand Five Hundred Twenty Eight Rupees and paise only). **Thirty Five Paise only** as on 31.07.2022 along with further interest within 60 days from the date of receipt of this notice.

The above named borrowers/guarantors having failed to repay the amount, notice is hereby given to the Borrower/Mortgagor/Guarantor and the public in general that they are hereby notified that the undersigned has taken possession of the immovable property in exercise of powers conferred on him/her under section 13(4) of said act read with Rule 8 & 9 of the said Rules, 2002, on this **13th day of October of the year 2025**.

It is hereby notified that the undersigned shall continue to hold possession of the property and hereby cautioned not to deal with the property and any dealings with the property will be subject to the charge of **Canara Bank, Asset Recovery Management Branch** and amount of Rs. **1,13,39,528.38** as on **31.10.2025**. (Rupees Thirteen Crore Ninety Lakhs Seven Thousand Two Hundred Sixty One rupees Ninety Nine paise only) and interest thereon.

The borrower's attention is invited to provisions of sub-section (9) of Section 13 (4) of the Act, in respect of the time available, to redeem the secured assets.

Address: 49 Floor, Market Street, Worli East, Mumbai - 400025.
Residential Plot No. 201 on 2nd Floor, Patanchi Wing I, S.R. No. 226, Kaveripatti Choudhury Road, Thane West Suburb, 401, Carpet area 602 Sq.ft. lies in the name of Mr. Rishabh Kumar Singh, R/o: 10/1, Durgam Cheruvu, Hyderabad - 500042, Telangana State, India H.Wing, On or Towards South - Main Road, On or Towards East : Main Gate Ganga Park Aps, On or Towards West : J WING

Date: 13.10.2025 _____
 Authorized Officer

[illegible]

FORTIS MALAR HOSPITALS LIMITED	
CIN: L55110PB1089PLC045948 Regd Office: Fortis Hospital Sector-62 Phase-VIII, Mohali, Punjab, India, 160062 Tel No: +91 172 4692222; FAX No: +91 172 5096002; Website: www.fortismalarhospital.com; e-mail: secretarial.malar@malarhospitals.in	
Recommendation of the Committee of Independent Directors ("CID") on the Open Offer by Northern TC Venture Pte. Ltd. ("Acquirer") along with HH Healthcare Behard ("PAC 1") and Parkway Pantai Limited ("PAC 2") to the Shareholders of Fortis Malar Hospitals Limited (the "Target Company") or "TC" (under Regulation 26(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI (SAST) Regulations")	
1. Date	October 15, 2025
2. Name of the Target Company (TC)	Fortis Malar Hospitals Limited
3. Details of the Offer pertaining to TC	Acquirer and PACs (defined below) are making an open offer to the equity shareholders of the Target Company to acquire up to 4,884,308 (Four Million Eight Hundred and Ninety Four Thousand Three Hundred and Eighty) fully paid up equity shares of face value of INR 10 (Rupees Ten) each, comprising of 26,11% (Twenty Six Point One Per cent) of the total voting equity share capital of the Target Company on a fully diluted basis pursuant to and in compliance with requirements of the SEBI (SAST) Regulations. Public Announcement dated July 13, 2018 (the "PA"); Detailed Public Statement dated November 19, 2018 (the "DPS"); Draft Letter of Offer dated November 29, 2018 (the "DLOF") and Letter of Offer dated October 4, 2020 (the "LoF") have been issued by HSBG Securities and Capital Markets (India) Private Limited (the "HSBG"), HFCB Bank Limited, Citigroup Global Markets India Private Limited, and Deutsche Equities India Private Limited, on behalf of the Acquirer and PACs. By way of brief background, it may be noted that the shareholders of the Target Company that the open offer was initiated vide the PA, pursuant to and upon the execution of a share subscription agreement between the parent of the Target Company (i.e., Fortis Healthcare Limited ("FHL")) and the Acquirer. The open offer price offered by the Acquirer and PACs to the shareholders of the Target Company was INR 60 (Indian Rupees Forty only) per Equity Share. Thereafter, the subscription transaction received requisite regulatory approvals, including from the Competition Commission of India, the stock exchanges, as well as the shareholders of FHL. Pursuant to the aforesaid approvals, the underlying share subscription transaction was consummated between FHL and the Acquirer on November 13, 2018. Subsequently, and after the subscription transaction between FHL and Acquirer had already been consummated, an ex parte order directing that status quo be maintained with respect to the sale of controlling stake in FHL (and indirectly) of the Target Company came to be passed by the Hon'ble Supreme Court of India on December 14, 2018 ("Status Quo Order"). In compliance with the Status Quo Order, the open offer process for FHL and the Target Company was put on hold. Basic legal principle, it is understood that pursuant to the Hon'ble Supreme Court of India final judgment dated September 22, 2022 ("2022 Judgment"), the Status Quo Order, being an interim order, ceases to exist and stands merged with the 2022 Judgment. Accordingly, given that the 2022 Judgment does not continue / extend the operation of the restraint imposed vide the Status Quo Order, as on date, there is no legal restraint on the open offer process. In the above backdrop, we understand basic communications and LoF issued by the Acquirer and PACs, that the open offer is now being recommenced in accordance with the orders and guidance received from Securities and Exchange Board of India (SEBI) vide its letter dated October 01, 2025 issued to HSBG Securities and Capital Markets (India) Private Limited (the "SEBI Letter"). It should also be noted that the Target Company sold its business operations pertaining to the Malar hospital, as a going concern, on a slump sale basis, in February 2024, pursuant to receipt of requisite corporate approvals as per applicable laws. Post the aforesaid divestment, the Target Company ceases to have any business operations, and the proceeds of the sale consideration were therefore distributed among the shareholders of the Target Company, in compliance with the applicable laws. Specifically, on April 12, 2024, the board of directors of the Target Company declared an interim dividend of INR 40 (Indian Rupees Forty only) per equity share and the shareholders of the Target Company, on July 31, 2024, approved the final dividend of INR 2.50 (Indian Rupees Two and Fifty Paise only) per equity share. Pursuant to the declaration and payment of the aforesaid interim dividend and final dividend, the open offer price was revised from the original open offer price of INR 60.10 (Indian Rupees Sixty and Ten Paise only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paise only), in accordance with the requirements of the SEBI (SAST) Regulations. As at the present date, the management of the Target Company has no visibility of commencing any new business operations in the future. In this regard, the Target Company's management and board of directors, in consultation with its legal advisors' merchant bankers, are evaluating various corporate restructuring options for the future possible course of actions for the Target Company. Open Offer Price: In accordance with the directions and guidance received from SEBI under the SEBI Letter, and as per the Revised LoF, we understand that the open offer price shall be – (i) INR 17.60 (Indian Rupees Seventeen and Sixty Paise only) per Equity Share plus interest amount of INR 18.36 (Indian Rupees Eighteen and Thirty Six Paise only) ("Applicable Interest") calculated at the rate of 10% (Ten Percent) per annum on INR 60 (Indian Rupees Forty only) – i.e., open offer price as per the PA, payable for the period from September 22, 2022 until November 19, 2025, for those shareholders of the Target Company who have been holding Equity Shares since December 24, 2018 (i.e., identified date under the DLoF) ("Original Shareholders"). Therefore, the total consideration payable by Acquirer and PACs to Original Shareholders who tender their Equity Shares as part of the open offer process shall be INR 35.96 (Indian Rupees Thirty Five and Ninety Six Paise only) per Equity Share; and (ii) INR 17.60 (Indian Rupees Seventeen and Sixty Paise only) per Equity Share for shareholders of the Target Company other than the Original Shareholders, i.e., shareholders of the Target Company who have acquired Equity Shares post December 24, 2018 (i.e., identified date under the DLoF). The open offer price (plus the Applicable Interest) shall be payable in cash in accordance with other terms and conditions of SEBI (SAST) Regulations.
4. Name(s) of the acquirer and PAC with the acquirer	1) Northern TC Venture Pte. Ltd. (Acquirer) 2) HH Healthcare Behard (PAC 1) 3) Parkway Pantai Limited (PAC 2)
5. Name of the Manager to the offer	1) HSBG Securities and Capital Markets (India) Private Limited 2) HFCB Bank Limited 3) Citigroup Global Markets India Private Limited 4) Deutsche Equities India Private Limited
6. Members of the Committee of Independent Directors (Please indicate the chairperson of the Committee separately)	1) Ms. Savitani Chakraborty, Chairperson 2) Mr. Shalaja Chandra, Member
7. IDB Member's relationship with the TC (Director, Equity shares owned, any other contract / relationship), if any	IDC members are independent directors on the board of the Target Company. None of the IDC members have any contractual relationship with the Target Company, other than their appointment as independent directors on the board of the Target Company.
8. Trading in the equity shares/other securities of the TC by IDC Members	None of the IDC members have traded in the equity shares or securities of Target Company, (i) during the 12-month period preceding the date of the PA, and (ii) during the period from the date of the PA and till the date of this recommendation.
9. IDB Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any	None of the IDC members: a) are directors of the Acquirer or PACs; b) hold any equity shares or other securities of the Acquirer or the PACs; and c) have any contract / relationship with the Acquirer or with the PACs.
10. Trading in the equity shares/other securities of the acquirer by IDC Members	None of the IDC members have traded in the equity shares or securities of the Acquirer or PACs, (i) during the 12-month period preceding the date of the PA; and (ii) during the period from the date of the PA and till the date of this recommendation.
11. Recommendation on the Open offer, as to whether the offer is fair and reasonable	IDC has perused the PA, DPS, DLoF and LoF published on behalf of the Acquirer and PACs. Morgan Stanley India Company Private Limited, has provided external advice dated October 15, 2025 to the IDC that the open offer price is in accordance with the provisions of the SEBI (SAST) Regulations and the directions of SEBI. The IDC has also taken into consideration the following: a) The open offer was initially made in 2018 and has been stalled since; b) The business operations of Malar hospital were divested in February 2024; c) An interim dividend of INR 40/- (Indian Rupees Forty Paise only) per equity share was declared to the shareholders of the Target Company on April 12, 2024, pursuant to the divestment of business operations of Malar hospital; d) A final dividend of INR 2.50/- (Indian Rupees Two and Fifty Paise only) per equity share for financial year 2023-24 was declared to the shareholders of the Target Company on July 31, 2024; and e) The original open offer price was reduced from INR 60.10 (Indian Rupees Sixty and Ten Paise only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paise only), pursuant to declaration of interim dividend and final dividend by the Target Company, in accordance with the requirements of the SEBI (SAST) Regulations. Basic review of the LoF, the IDC notes that SEBI has also awarded the Applicable Interest on the open offer price to the Original Shareholders on account of the delay in the open offer process, in accordance with the provisions of the SEBI (SAST) Regulations. IDC understands that SEBI has factored in all these aspects concerning the open offer, and thereafter, in exercise of its regulatory powers under the SEBI (SAST) Regulations, has determined the open offer price and awarded Applicable Interest vide the SEBI Letter. Based on perusal of the LoF, the IDC understands that the open offer price is (i) INR 17.60 (Indian Rupees Seventeen and Sixty Paise only) per Equity Share plus interest amount of INR 18.36 (Indian Rupees Eighteen and Thirty Six Paise only) calculated at the rate of 10% (Ten Percent) per annum on INR 58 (Indian Rupees Fifty Eight only) – i.e., open offer price as per the PA, payable for the period from September 22, 2022 until November 19, 2025, for those shareholders of the Target Company who have been holding Equity Shares since December 24, 2018 (i.e., identified date under the DLoF); and (ii) INR 17.60 (Indian Rupees Seventeen and Sixty Paise only) per Equity Share for shareholders of the Target Company other than the Original Shareholders, i.e., shareholders of the Target Company who have acquired Equity Shares post December 24, 2018 (i.e., identified date under the DLoF). Based on the above and in light of the advice received, the IDC is of the opinion that the aforesaid open offer price is in compliance with the requirements of the SEBI (SAST) Regulations and in accordance with the directions of SEBI, for both the Original Shareholders as well as shareholders other than the Original Shareholders, and to that extent, from a regulatory and legal perspective, is fair and reasonable. The IDC would like to additionally point out that post the aforesaid divestment of the business operations of Malar hospital, the Target Company ceases to have any business operations. As of the present date, the management of the Target Company has no visibility of commencing any new business operations in the future. In this regard, the Target Company's management and board of directors, in consultation with its legal advisors' merchant bankers, are evaluating various corporate restructuring options for the future possible course of actions for the Target Company. IDC would like to highlight that the current market price of the Equity Shares of the Target Company is higher than the open offer price. The IDC members suggest that the shareholders of the Target Company should independently evaluate the open offer and take an informed decision in respect of the open offer taking into account all the factors and considerations, mentioned above.
12. Summary of reasons for recommendation (IDC may also invite attention to any other place, e.g. company's website, where its detailed recommendations along with written advice of the independent adviser, if any can be seen by the shareholder)	IDC has perused the PA, DPS, DLoF and LoF published on behalf of the Acquirer and PACs, the advice dated October 15, 2025 provided by Morgan Stanley India Company Private Limited and the legal opinion dated October 15, 2025 provided by Saraf and Partners. The IDC has also taken into consideration the following for making the recommendation: a) The open offer was initially made in 2018 and has been stalled since; b) The business operations of Malar hospital were divested in February 2024; c) An interim dividend of INR 40/- (Indian Rupees Forty Paise only) per equity share was declared to the shareholders of the Target Company on April 12, 2024, pursuant to the divestment of business operations of Malar hospital; d) A final dividend of INR 2.50/- (Indian Rupees Two and Fifty Paise only) per equity share for financial year 2023-24 was declared to the shareholders of the Target Company on July 31, 2024; and e) The original open offer price was reduced from INR 60.10 (Indian Rupees Sixty and Ten Paise only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paise only), pursuant to declaration of interim dividend and final dividend by the Target Company, in accordance with the requirements of the SEBI (SAST) Regulations. Basic review of the LoF, the IDC notes that SEBI has also awarded the Applicable Interest on the open offer price to the Original Shareholders on account of the delay in the open offer process, in accordance with the provisions

THE BUSINESS DAILY.

FINANCIAL EXPRESS

FOR DAILY BUSINESS.

financialexpress.com

